Adverse effects: 1. General ‐ overall number of events · people with psychosis
Any antiglucocorticoid probably leads to higher adverse effects: 1. General ‐ overall number of events compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events: 2. Specific ‐ extrapyramidal symptoms ‐ average endpoint scores ‐ data only for DHEA SHRS total · people with psychosis
1 finding from 1 review
Mean depression scores ‐ HAMD · people with psychosis
1 finding from 1 review
no estimate extracted
1 study · 5 participants
Very low
Global state: 1. General ‐ no clinically significant improvement ‐ short term < 30% improvement on BPRS · people with psychosis
Any antiglucocorticoid may leads to lower global state: 1. General ‐ no clinically significant improvement ‐… compared with placebo (low certainty).
1 finding from 1 review
Global state: 2. Specific: positive ‐ no clinically significant improvement ‐ short term (< 50% improvement on BPRS PSS) · people with psychosis
Any antiglucocorticoid may leads to lower global state: 2. Specific: positive ‐ no clinically significant… compared with placebo (low certainty).
1 finding from 1 review
Global state: improvement, short term PANSS · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in global state: improvement, short term PANSS compared with placebo (low certainty).
1 finding from 1 review
Mental state: General ‐ average total score (PANSS, high = poor) ‐ up to 12 weeks (short‐term) · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
General functioning ‐ short term GAS · patients with schizophrenia
1 finding from 1 review
General functioning ‐ medium term GAS · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in leaving the study early, short term compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Serious (any time point) ‐ any serious adverse effect Various methods · patients with schizophrenia
Adjunctive antioxidants for schizophrenia showed no clear difference in adverse effects: 1. Serious (any time point) ‐ any serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Improvement in nutritional intake · participants with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Change in measures of nutritional status: weight (kg), body mass index (kg/ m2), and waist/ hip ratio (cms) · participants with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mental state · participants with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Clinically important adverse effects · participants with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Measures of physiological function · participants with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HIV infection · people with serious mental illness
1 finding from 1 review
Number of participants with improved quality of life · people with serious mental illness
1 finding from 1 review
Adverse events · people with serious mental illness
1 finding from 1 review